Trial Profile

A real-world postmarketing safety and efficacy study of edaravone for amyotrophic lateral sclerosis

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 16 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Edaravone (Primary)
Indications Amyotrophic lateral sclerosis
Focus Adverse reactions; Therapeutic Use

Most Recent Events

11 Mar 2022 According to a Mitsubishi Tanabe Pharma America media release, data from this study will be presented at the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
11 Dec 2020 According to a Soleo Health media release, results from this study were presented at the Motor Neurone Disease Association (MNDA) 31st International Symposium on ALS/MND.
11 Dec 2020 Results presented in a Soleo Health media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com